ResMed Inc.

RMD Healthcare Medical Instruments & Supplies

ResMed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $5.7 billion, up 9.85% from fiscal 2025. In the quarter to June 2026, revenue grew 8.58%, EPS grew 2.32%, free cash flow fell 21.3% and total debt fell 39.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten, operating cash flow growth for three.

238.97 3.26 −1.35%
Market cap
$34.1B
P/E
22.8×
Fwd P/E
16.6×
Dividend yield
1.03%
F-score
6/9
Altman Z
10.00
Beneish M
−2.59
Dividend safety
96/100

ResMed Inc. (RMD) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, ResMed Inc. (RMD) trades at a EV/FCF of 20.7×. Over the past ten years it has ranged from 12.5× (January 2016) to 185× (August 2022); the current reading is higher than 24% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2026 16.8× (25.84%)
FY2025 22.6× 4.02%
FY2024 21.7× (63.49%)
FY2023 59.5× (62.69%)
FY2022 159× 173.27%
FY2021 58.3× 42.99%
FY2020 40.8× (17.25%)
FY2019 49.3× 43.52%
FY2018 34.4× 4.50%
FY2017 32.9× 75.22%

Quarterly newest first

Period EV/FCF Change
Jun 2026 16.8× (7.26%)
Mar 2026 18.1× (5.91%)
Dec 2025 19.2× (13.60%)
Sep 2025 22.2× (1.63%)
42 more quarters

Against its own ten years

Low 12.5× High 185×
Ten-year median 32.9×
Current reading's percentile 18

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on RMD